Compare Abbott Laboratories (ABT) vs S&P Global Inc (SPGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs S&P Global Inc — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while S&P Global Inc trades at $432.88 (market cap $131.26B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SPGI | |
|---|---|---|
Market Cap | $166.94B | $131.26B |
Sector | Health | Financials |
52-Week High | $136.62 | $534.79 |
52-Week Low | $82.57 | $370.42 |
Enterprise Value | $193.69B | $143.23B |
Dividend Yield | 2.63% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
S&P Global (SPGI) trades at $443.46, up 0.81% with strong bullish momentum. The stock shows robust fundamentals with 29.15% net margin and consistent earnings beats in three of the last four quarters. Recent completion of Mobility Global spinoff and AI-driven market intelligence initiatives position the company for growth. Technical indicators show bullish moving averages while RSI suggests potential overbought conditions near-term.
Outlook remains positive with 85.7% analyst buy ratings and $533.50 consensus target implying 20% upside. Key risks include interest rate sensitivity in credit rating segment and execution of AI transformation. The company's subscription-based revenue model and market data dominance provide stable cash flow foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
